StockMacro
Company, fund or insider

Help

Menu

Phibro Animal Health

$33.29 -1.2% in 6 monthsMarket cap $1.4B

PAHC on XNAS, Health Care, Phibro Animal Health Corporation, job postings

Measures activity, not value. Not investment advice.

Net income rose 51% to $102.7M in 12 months while the share price fell 18%.

  • WatchFree cash flow was just $21.7M over the last 12 months
  • GoodInstitutional holders rose 14% to 233 from 204 filers

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Phibro Animal Health Corp is a world-wide diversified animal health and mineral nutrition company. It strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. It develop, manufacture and market products for food animals including poultry, beef and dairy cattle, swine, aquaculture and dogs. It has three segments Animal Health, Mineral Nutrition, and Performance Products. Majority of revenue comes from Animal Health segment. Animal health products are anti-bacterials, anticoccidials, nutritional specialty products, and vaccines, and vaccine adjuvants that help improve the animal's health.

Industry
Pharmaceutical preparations (Health Care)
Employees
2,605
Website
pahc.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 3 Feb 2027 (an estimate: a year ago it reported on 4 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $386.8M, net income $29.5M.
Quarter to 31 Dec 2021: revenue $232.7M, net income $17.5MQuarter to 31 Dec 2021: revenue $232.7M, net income $17.5MQuarter to 31 Mar 2022: revenue $239.6M, net income $17.7MQuarter to 31 Mar 2022: revenue $239.6M, net income $17.7MQuarter to 30 Jun 2022: revenue $255.3M, net income $7.5MQuarter to 30 Jun 2022: revenue $255.3M, net income $7.5MQuarter to 30 Sep 2022: revenue $232.5M, net income $3.9MQuarter to 30 Sep 2022: revenue $232.5M, net income $3.9MQuarter to 31 Dec 2022: revenue $244.6M, net income $7.2MQuarter to 31 Dec 2022: revenue $244.6M, net income $7.2MQuarter to 31 Mar 2023: revenue $245.7M, net income $10.0MQuarter to 31 Mar 2023: revenue $245.7M, net income $10.0MQuarter to 30 Jun 2023: revenue $255.0M, net income $11.5MQuarter to 30 Jun 2023: revenue $255.0M, net income $11.5MQuarter to 30 Sep 2023: revenue $231.3M, net income -$8.0MQuarter to 30 Sep 2023: revenue $231.3M, net income -$8.0MQuarter to 31 Dec 2023: revenue $249.9M, net income $1.3MQuarter to 31 Dec 2023: revenue $249.9M, net income $1.3MQuarter to 31 Mar 2024: revenue $263.2M, net income $8.4MQuarter to 31 Mar 2024: revenue $263.2M, net income $8.4MQuarter to 30 Jun 2024: revenue $273.2M, net income $752KQuarter to 30 Jun 2024: revenue $273.2M, net income $752KQuarter to 30 Sep 2024: revenue $260.4M, net income $7.0MQuarter to 30 Sep 2024: revenue $260.4M, net income $7.0MQuarter to 31 Dec 2024: revenue $309.3M, net income $3.2MQuarter to 31 Dec 2024: revenue $309.3M, net income $3.2MQuarter to 31 Mar 2025: revenue $347.8M, net income $20.9MQuarter to 31 Mar 2025: revenue $347.8M, net income $20.9MQuarter to 30 Jun 2025: revenue $378.7M, net income $17.2MQuarter to 30 Jun 2025: revenue $378.7M, net income $17.2MQuarter to 30 Sep 2025: revenue $363.9M, net income $26.5MQuarter to 30 Sep 2025: revenue $363.9M, net income $26.5MQuarter to 31 Dec 2025: revenue $373.9M, net income $27.5MQuarter to 31 Dec 2025: revenue $373.9M, net income $27.5MQuarter to 31 Mar 2026: revenue $383.5M, net income $24.0MQuarter to 31 Mar 2026: revenue $383.5M, net income $24.0MQuarter to 30 Jun 2026: revenue $396.7M, net income $21.7MQuarter to 30 Jun 2026: revenue $396.7M, net income $21.7MQuarter to 30 Sep 2026: revenue $386.8M, net income $29.5MQuarter to 30 Sep 2026: revenue $386.8M, net income $29.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $396.7M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$386.8M$29.5M
30 Jun 2026$396.7M$21.7M
31 Mar 2026$383.5M$24.0M
31 Dec 2025$373.9M$27.5M
30 Sep 2025$363.9M$26.5M
30 Jun 2025$378.7M$17.2M
31 Mar 2025$347.8M$20.9M
31 Dec 2024$309.3M$3.2M
30 Sep 2024$260.4M$7.0M
30 Jun 2024$273.2M$752K
31 Mar 2024$263.2M$8.4M
31 Dec 2023$249.9M$1.3M
30 Sep 2023$231.3M-$8.0M
30 Jun 2023$255.0M$11.5M
31 Mar 2023$245.7M$10.0M
31 Dec 2022$244.6M$7.2M
30 Sep 2022$232.5M$3.9M
30 Jun 2022$255.3M$7.5M
31 Mar 2022$239.6M$17.7M
31 Dec 2021$232.7M$17.5M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.5B $1.4B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +10% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $102.7M $67.8M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $2.51 $1.67
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 33.8% 31.2% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 12.5% 10.3% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 6.7% 4.8% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 28.2% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $21.7M $34.3M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $83.1M $85.3M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 13.2 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 0.88 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 3.2 2.0
Dividend yieldDividends per share declared in the latest fiscal year divided by the share price. 1.4% 2.5%

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Phibro Animal HealthPAHC (this company) $1.4B13.20.88+10%6.7%
UroGen PharmaURGN $1.4Bloss5.4+159%-26.3%
uniQureQURE $1.4Bloss67.3+28%–
Nuvation BioNUVB $1.3Bloss6.6+654%-67.4%
Rapport TherapeuticsRAPP $1.4Bloss–––
AnaptysBioANAB $1.4B7.57.2+13%96.3%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+6.3%

$386.8M vs $363.9M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+36%

$18.8M vs $13.8M (quarter ended 30 Sep 2026)

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+14%

233 13F filers vs 204

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

–

No 13F holdings or share count.

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

–

1.0M shares sold short (30 Oct 2026); no share count in the company's filings in our data

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

6.4

1.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-1.3%

1.0M shares sold short in the report before, 1.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

64%

64% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 52%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

40

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$720K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

9

9 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

3.0×

9 articles in the last 7 days; its usual week has 3.

Price $33.29 on 20 Nov 2026, -18% over 12 months (12-month range $28.52 to $59.58)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $23.1M in the last 12 months (the 12 months before: -$8.4M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
Revenue per quarter. Revenue $386.8M in the latest quarter, +6.3% on a year earlier.
Capital spending per quarter. Capital spending $18.8M in the latest quarter, +36% on a year earlier.
Institutional holders (13F filers). 233 13F filers reported holding it in the latest 13F quarter, +14% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.
Lobbying spend. Lobbying spend: $720K published in the last 12 months, +125% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
26 Jun 20268-K and other filingsDirector or officer change
14 Apr 20268-K and other filingsDirector or officer change
14 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Dec 20258-K and other filingsDirector or officer change
18 Dec 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Oct 2025Lobbying filingnew lobbying registration (MILNE, WIENER & SHOFE GLOBAL STRATEGIES (FKA M & W GOVERNMENT AFFAIRS, LLC))
28 Aug 2025Sharp changeQuarterly revenue change: quarterly revenue change, 378.7M vs usual 261.8M (2025-06-30); 1.4x the same period a year earlier
21 Jul 2025Sharp changeLobbying on a new issue: lobbying on a new issue: SCI (2025-06-30)
15 May 2025Lobbying filingnew lobbying registration (CHECKMATE GOVERNMENT RELATIONS)
8 May 2025Sharp changeQuarterly revenue change: quarterly revenue change, 347.8M vs usual 257.7M (2025-03-31); 1.3x the same period a year earlier
18 Feb 2025Sharp changeMany funds opening a new position: many funds opening a new position, 35 vs usual 12 (2024-12-31); 1.9x the same period a year earlier
23 Jan 20258-K and other filingsDirector or officer change
12 Nov 20248-K and other filingsDirector or officer change
12 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Oct 20248-K and other filingsCompleted an acquisition or asset sale
13 Feb 2024Sharp changeShort interest spike: short interest spike, 937K vs usual 482K (2024-01-31); 2.2x the same period a year earlier
6 Feb 20248-K and other filingsDirector or officer change
6 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Jan 2024Sharp changeShort interest spike: short interest spike, 880K vs usual 469K (2024-01-12); 2.1x the same period a year earlier
16 Jan 2024Sharp changeShort interest spike: short interest spike, 874K vs usual 457K (2023-12-29); 2.0x the same period a year earlier
2 Jan 2024Sharp changeShort interest spike: short interest spike, 947K vs usual 455K (2023-12-15); 2.1x the same period a year earlier
12 Dec 2023Sharp changeShort interest spike: short interest spike, 958K vs usual 441K (2023-11-30); 2.5x the same period a year earlier
28 Nov 2023Sharp changeShort interest spike: short interest spike, 762K vs usual 441K (2023-11-15); 1.4x the same period a year earlier
5 Sep 20238-K and other filingsDirector or officer change
6 Jul 20238-K and other filingsDirector or officer change
6 Jul 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 Feb 20238-K and other filingsDirector or officer change
6 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Nov 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 23.2M vs usual 7.5M (2022-09-30); 3.1x the same period a year earlier
3 Oct 2022Lobbying filinglobbying engagement terminated (VICKI J HICKS)
30 Aug 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 11.9M vs usual 7.5M (2022-06-30); 1.7x the same period a year earlier
25 Jul 2022Lobbying filinglobbying engagement terminated (A2 STRATEGIES, LLC)
Insider net buying (open market)
Month from 1 Sep 2024: $100K published
Month from 1 Feb 2025: $110K published
Month from 1 Sep 2025: -$1.1M published
Month from 1 Oct 2025: -$2.7M published
Month from 1 Nov 2025: -$4.7M published
Month from 1 Dec 2025: -$1.0M published
Month from 1 Jan 2026: -$1.8M published
Month from 1 Feb 2026: -$12.7M published
Month from 1 Mar 2026: -$2.6M published
Month from 1 Apr 2026: -$3.1M published
Month from 1 May 2026: -$2.2M published
Month from 1 Jun 2026: $318K published
H-1B/E-3 applications certified
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jan 2025: 1 published
Quarter from 1 Apr 2025: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $232.7M, +13% on a year earlier; public on 10 Feb 2022
Quarter ended 31 Mar 2022: $239.6M, +13% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $255.3M, +16% on a year earlier; public on 25 Aug 2022
Quarter ended 30 Sep 2022: $232.5M, +8.3% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $244.6M, +5.1% on a year earlier; public on 9 Feb 2023
Quarter ended 31 Mar 2023: $245.7M, +2.5% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $255.0M, -0.1% on a year earlier; public on 31 Aug 2023
Quarter ended 30 Sep 2023: $231.3M, -0.5% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $249.9M, +2.2% on a year earlier; public on 8 Feb 2024
Quarter ended 31 Mar 2024: $263.2M, +7.1% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $273.2M, +7.1% on a year earlier; public on 29 Aug 2024
Quarter ended 30 Sep 2024: $260.4M, +13% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $309.3M, +24% on a year earlier; public on 6 Feb 2025
Quarter ended 31 Mar 2025: $347.8M, +32% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $378.7M, +39% on a year earlier; public on 28 Aug 2025
Quarter ended 30 Sep 2025: $363.9M, +40% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $373.9M, +21% on a year earlier; public on 5 Feb 2026
Quarter ended 31 Mar 2026: $383.5M, +10% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $396.7M, +4.8% on a year earlier; public on 27 Aug 2026
Quarter ended 30 Sep 2026: $386.8M, +6.3% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $7.7M, +5.1% on a year earlier; public on 10 Feb 2022
Quarter ended 31 Mar 2022: $10.0M, +34% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $11.9M, +68% on a year earlier; public on 25 Aug 2022
Quarter ended 30 Sep 2022: $23.2M, +211% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $9.8M, +28% on a year earlier; public on 9 Feb 2023
Quarter ended 31 Mar 2023: $7.9M, -21% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $10.9M, -8.4% on a year earlier; public on 31 Aug 2023
Quarter ended 30 Sep 2023: $7.5M, -68% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $11.0M, +12% on a year earlier; public on 8 Feb 2024
Quarter ended 31 Mar 2024: $9.7M, +23% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $13.1M, +20% on a year earlier; public on 29 Aug 2024
Quarter ended 30 Sep 2024: $9.6M, +28% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $7.8M, -29% on a year earlier; public on 6 Feb 2025
Quarter ended 31 Mar 2025: $7.7M, -20% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $13.1M, +0.5% on a year earlier; public on 28 Aug 2025
Quarter ended 30 Sep 2025: $13.8M, +44% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $11.1M, +42% on a year earlier; public on 5 Feb 2026
Quarter ended 31 Mar 2026: $15.3M, +98% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $18.9M, +44% on a year earlier; public on 27 Aug 2026
Quarter ended 30 Sep 2026: $18.8M, +36% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 129; public on 14 Feb 2022
31 Mar 2022 report: 143; public on 16 May 2022
30 Jun 2022 report: 139; public on 15 Aug 2022
30 Sep 2022 report: 140; public on 14 Nov 2022
31 Dec 2022 report: 121; public on 14 Feb 2023
31 Mar 2023 report: 126; public on 15 May 2023
30 Jun 2023 report: 117; public on 14 Aug 2023
30 Sep 2023 report: 117; public on 14 Nov 2023
31 Dec 2023 report: 128; public on 14 Feb 2024
31 Mar 2024 report: 132; public on 15 May 2024
30 Jun 2024 report: 132; public on 14 Aug 2024
30 Sep 2024 report: 141; public on 14 Nov 2024
31 Dec 2024 report: 168; public on 14 Feb 2025
31 Mar 2025 report: 178; public on 15 May 2025
30 Jun 2025 report: 183; public on 14 Aug 2025
30 Sep 2025 report: 205; public on 14 Nov 2025
31 Dec 2025 report: 219; public on 17 Feb 2026
31 Mar 2026 report: 248; public on 15 May 2026
30 Jun 2026 report: 204; public on 14 Aug 2026
30 Sep 2026 report: 233; public on 16 Nov 2026
Federal obligations
Month from 1 Mar 2024: $210K published
Month from 1 Jan 2025: $0 published
Lobbying spend
Quarter from 1 Jan 2022: $15K published
Quarter from 1 Apr 2022: $20K published
Quarter from 1 Oct 2024: $60K published
Quarter from 1 Jul 2025: $150K published
Quarter from 1 Oct 2025: $170K published
Quarter from 1 Jan 2026: $180K published
Quarter from 1 Apr 2026: $180K published
Quarter from 1 Jul 2026: $180K published
Quarter from 1 Oct 2026: $180K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $318K (2 Jun 2026), higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $23.1M in the last 12 months (the 12 months before: -$8.4M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
  • Revenue per quarter: Revenue $386.8M in the latest quarter, +6.3% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

No trades in the last 90 days; the latest was filed 2 Jun 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
2 Jun 2026E Thomas CorcoranDirectorBuy10,000$31.77$318KForm 4
7 May 2026Jack Bendheim and 1 otherPresident and CEOSellplanned in advance (10b5-1)18,608$54.62$1.0MForm 4
30 Apr 2026Jack Bendheim and 1 otherPresident and CEOSellplanned in advance (10b5-1)21,120$53.86$1.1MForm 4
23 Apr 2026Jack Bendheim and 1 otherPresident and CEOSellplanned in advance (10b5-1)21,120$54.79$1.2MForm 4
16 Apr 2026BFI Co., LLC and 1 other10% ownerSellplanned in advance (10b5-1)21,120$56.89$1.2MForm 4
31 Mar 2026Jack Bendheim and 1 otherPresident and CEOSellplanned in advance (10b5-1)14,080$53.75$757KForm 4
26 Mar 2026Jack Bendheim and 1 otherPresident and CEOSellplanned in advance (10b5-1)21,120$55.21$1.2MForm 4
19 Mar 2026Jack Bendheim and 1 otherPresident and CEOSellplanned in advance (10b5-1)22,880$52.40$1.2MForm 4

233 institutions reported shares at the end of Q3 2026; 43 opened a position, 20 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)3.3M$116.7M+106K+3.4%
BlackRock, Inc.3.2M$116.0M+28K+0.9%
State Street Corp1.0M$37.3M+5,935+0.6%
CastleKnight Management LP975K$34.8M+514K+111%
Vanguard Capital Management LLC920K$32.9M-3,469-0.4%
Millennium Management LLC823K$29.4M-114K-12%
Lord, Abbett & Co. LLC644K-9,072-1.4%
Geode Capital Management, LLC610K$21.8M-47K-7.2%
Dimensional Fund Advisors LP539K$19.2M+7,419+1.4%
Vanguard Portfolio Management LLC473K$16.9M-36K-7.0%

Company events

All 28 company events

In 12 months: 3 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
26 Jun 2026Director or officer change8-K
30 Apr 2026Signed a major agreementSame filing: took on new debt8-K
14 Apr 2026Director or officer change8-K
18 Dec 2025Director or officer change8-K
23 Jan 2025Director or officer change8-K
12 Nov 2024Director or officer change8-K
31 Oct 2024Completed an acquisition or asset saleSame filing: took on new debt8-K
9 Jul 2024Signed a major agreementSame filing: took on new debt8-K

40 open postings; careers site tracked since 21 Nov 2026. Most in Manufacturing & production 30%, Sales & business development 12%, Test, quality & reliability 10%, Supply chain & procurement 8%.

PostedJobLocation
21 Nov 2026or earlierArchitect, Master Data ManagementSoftware engineeringTeaneck, New Jersey
21 Nov 2026or earlierLearning & Development Manager - MACIE RegionPeople & recruitingאיירפורט סיטי, מרכז, IL
21 Nov 2026or earlierQA SpecialistTest, quality & reliabilitySligo, Ireland, IE
21 Nov 2026or earlierQuality Systems ManagerTest, quality & reliabilitySligo, Ireland, IE
21 Nov 2026or earlierPersonal Care Sales Representative - PhibroChemSales & business developmentTeaneck, New Jersey
21 Nov 2026or earlierProject EngineerProgram & project managementבית שמש, מזרח (אזור ירושלים), IL
21 Nov 2026or earlierמנהל.ת מכירות צפוןיקנעם, צפון, IL
21 Nov 2026or earlierQuality Assurance SpecialistFinance & accountingQuincy, Illinois

Reported lobbying spend: $180K in Q3 2026, $180K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
7 Oct 2025NewMilne, Wiener & Shofe Global Strategies (Fka M & W Government Affairs, LLC)for Phibro Animal Health CorporationAdvocating for medicines to benefit the health and survivability of newborn pigsAgricultureFiling
1 Apr 2025NewCheckmate Government Relationsfor Phibro Animal Health CorporationIssues regarding regulatory methods of testing veterinary drugs.ANI, Science/technologyFiling
31 Aug 2022EndedVicki J Hicksfor A2 Strategies, LLC Obo Phibro Animal Health CorporationNot statedFiling
31 Mar 2022EndedA2 Strategies, LLCfor Phibro Animal Health Corporationanimal health and nutritionAgricultureFiling
17 May 2021NewVicki J Hicksfor A2 Strategies, LLC Obo Phibro Animal Health CorporationAnimal health issuesANI, PharmacyFiling
31 Mar 2021NewA2 Strategies, LLCfor Phibro Animal Health Corporationanimal health and nutritionANIFiling
30 Jun 2020EndedCovington & Burling LLPfor Phibro Animal Health CorporationNot statedFiling
18 Dec 2018NewCovington & Burling LLPfor Phibro Animal Health CorporationResolving any possible customs or regulatory barriers to the importation of its products into Indonesia.Government issuesFiling

The 5 newest of 141 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

3 Sep 2019confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Phibro Animal Health (PAHC): had 839K shares sold short in the 15 Aug 2019 report, 5.7× the same report last year, while it spent $10.1M on capital projects in the quarter ended 30 Jun 2019, 1.8× the same quarter last year. Two unrelated kinds of activity within 21 days.

  • Short interest and volume: Short interest spike, became public on 10 Aug 2019
  • Short interest and volume: Short interest spike, became public on 27 Aug 2019
  • Financials: Quarterly capital spending jump, became public on 3 Sep 2019
2018-08-15: 146K2018-08-31: 180K2018-09-14: 241K2018-09-28: 318K2018-10-15: 363K2018-10-31: 443K2018-11-15: 371K2018-11-30: 362K2018-12-14: 415K2018-12-31: 404K2019-01-15: 414K2019-01-31: 425K2019-02-15: 426K2019-02-28: 413K2019-03-15: 456K2019-03-29: 447K2019-04-15: 534K2019-04-30: 642K2019-05-15: 592K2019-05-31: 437K2019-06-14: 622K2019-06-28: 689K2019-07-15: 612K2019-07-31: 797K2019-08-15: 839K
The 15 Aug 2019 report against the 24 reports before it. this reportearliernormal: 425K
See the evidence (3 changes)

Short interest and volume: Short interest spike became public on 10 Aug 2019

Phibro Animal Health had 797K shares sold short in the 31 Jul 2019 report, 4.4× the same report last year.

This period
797K (the 31 Jul 2019 report)
Normal report (median of 24 earlier)
420K
Typical spread (median absolute deviation)
57K
How far from its usual level
+4.4
Same report last year
182K
History used
579 days
2018-07-31: 182K2018-08-15: 146K2018-08-31: 180K2018-09-14: 241K2018-09-28: 318K2018-10-15: 363K2018-10-31: 443K2018-11-15: 371K2018-11-30: 362K2018-12-14: 415K2018-12-31: 404K2019-01-15: 414K2019-01-31: 425K2019-02-15: 426K2019-02-28: 413K2019-03-15: 456K2019-03-29: 447K2019-04-15: 534K2019-04-30: 642K2019-05-15: 592K2019-05-31: 437K2019-06-14: 622K2019-06-28: 689K2019-07-15: 612K2019-07-31: 797K
the 31 Jul 2019 report24 earlier reportsnormal: 420K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Aug 2019

Phibro Animal Health had 839K shares sold short in the 15 Aug 2019 report, 5.7× the same report last year.

This period
839K (the 15 Aug 2019 report)
Normal report (median of 24 earlier)
425K
Typical spread (median absolute deviation)
63K
How far from its usual level
+4.5
Same report last year
146K
History used
594 days
2018-08-15: 146K2018-08-31: 180K2018-09-14: 241K2018-09-28: 318K2018-10-15: 363K2018-10-31: 443K2018-11-15: 371K2018-11-30: 362K2018-12-14: 415K2018-12-31: 404K2019-01-15: 414K2019-01-31: 425K2019-02-15: 426K2019-02-28: 413K2019-03-15: 456K2019-03-29: 447K2019-04-15: 534K2019-04-30: 642K2019-05-15: 592K2019-05-31: 437K2019-06-14: 622K2019-06-28: 689K2019-07-15: 612K2019-07-31: 797K2019-08-15: 839K
the 15 Aug 2019 report24 earlier reportsnormal: 425K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly capital spending jump became public on 3 Sep 2019

Phibro Animal Health spent $10.1M on capital projects in the quarter ended 30 Jun 2019, 1.8× the same quarter last year.

This period
$10.1M (the quarter ended 30 Jun 2019)
Normal quarter (median of 8 earlier)
$5.3M
Typical spread (median absolute deviation)
$618K
How far from its usual level
+4.9
Same quarter last year
$5.5M
History used
2,099 days
2017-03-31: $4.8M2017-06-30: $5.5M2017-09-30: $5.0M2017-12-31: $3.9M2018-03-31: $4.2M2018-06-30: $5.5M2018-09-30: $6.0M2019-03-31: $7.7M2019-06-30: $10.1M
the quarter ended 30 Jun 20198 earlier quartersnormal: $5.3M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 26 Jun 2026Filings record

    Director or officer change

  2. 3 Jun 2026Insiders record

    CORCORAN E THOMAS (director) bought 10,000 shares of PAHC ($317,700) (dated 2 Jun 2026)

  3. 14 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 14 Apr 2026Filings record

    Director or officer change

  5. 18 Dec 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 18 Dec 2025Filings record

    Director or officer change

  7. 8 Oct 2025Lobbying record

    PHIBRO ANIMAL HEALTH CORPORATION: new lobbying registration (MILNE, WIENER & SHOFE GLOBAL STRATEGIES (FKA M & W GOVERNMENT AFFAIRS, LLC)) (dated 7 Oct 2025)

  8. 28 Aug 2025Financials change

    reported revenue of $378.7M for the quarter ended 30 Jun 2025, 1.4× the same quarter last year.

    Same quarter last year: $273.2M; its normal quarter is $261.8M.

    See the evidence
    This period
    $378.7M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $261.8M
    Typical spread (median absolute deviation)
    $11.6M
    How far from its usual level
    +4.5
    Same quarter last year
    $273.2M
    History used
    3,378 days
    2023-06-30: $255.0M2023-09-30: $231.3M2023-12-31: $249.9M2024-03-31: $263.2M2024-06-30: $273.2M2024-09-30: $260.4M2024-12-31: $309.3M2025-03-31: $347.8M2025-06-30: $378.7M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $261.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  9. 21 Jul 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['SCI']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4837109
  10. 15 May 2025Lobbying record

    PHIBRO ANIMAL HEALTH CORPORATION: new lobbying registration (CHECKMATE GOVERNMENT RELATIONS) (dated 1 Apr 2025)

  11. 8 May 2025Financials change

    reported revenue of $347.8M for the quarter ended 31 Mar 2025, 1.3× the same quarter last year.

    Same quarter last year: $263.2M; its normal quarter is $257.7M.

    See the evidence
    This period
    $347.8M (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $257.7M
    Typical spread (median absolute deviation)
    $9.9M
    How far from its usual level
    +3.5
    Same quarter last year
    $263.2M
    History used
    3,287 days
    2023-03-31: $245.7M2023-06-30: $255.0M2023-09-30: $231.3M2023-12-31: $249.9M2024-03-31: $263.2M2024-06-30: $273.2M2024-09-30: $260.4M2024-12-31: $309.3M2025-03-31: $347.8M
    the quarter ended 31 Mar 20258 earlier quartersnormal: $257.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  12. 27 Feb 2025Insiders record

    CORCORAN E THOMAS (director) bought 5,000 shares of PAHC ($110,500) (dated 26 Feb 2025)

  13. 14 Feb 2025Institutional holdings change

    saw 35 13F filers open a new position in the quarter ended 31 Dec 2024, 1.9× the same quarter last year.

    Same quarter last year: 18; its normal quarter is 12.

    See the evidence
    This period
    35 (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    12
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +7.7
    Same quarter last year
    18
    History used
    3,837 days
    2022-12-31: 82023-03-31: 132023-06-30: 112023-09-30: 112023-12-31: 182024-03-31: 152024-06-30: 112024-09-30: 172024-12-31: 35
    the quarter ended 31 Dec 20248 earlier quartersnormal: 12

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  14. 23 Jan 2025Filings record

    Director or officer change

  15. 12 Nov 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  16. 12 Nov 2024Filings record

    Director or officer change

  17. 31 Oct 2024Filings record

    Completed an acquisition or asset sale

  18. 7 Sep 2024Insiders record

    CORCORAN E THOMAS (director) bought 5,000 shares of PAHC ($100,100) (dated 6 Sep 2024)

  19. 10 Feb 2024Short interest and volume change

    had 937K shares sold short in the 31 Jan 2024 report, 2.2× the same report last year.

    Same report last year: 431K; its normal report is 482K.

    See the evidence
    This period
    937K (the 31 Jan 2024 report)
    Normal report (median of 24 earlier)
    482K
    Typical spread (median absolute deviation)
    80K
    How far from its usual level
    +3.8
    Same report last year
    431K
    History used
    2,224 days
    2023-01-31: 431K2023-02-15: 493K2023-02-28: 492K2023-03-15: 515K2023-03-31: 560K2023-04-14: 474K2023-04-28: 491K2023-05-15: 449K2023-05-31: 385K2023-06-15: 396K2023-06-30: 399K2023-07-14: 433K2023-07-31: 373K2023-08-15: 370K2023-08-31: 388K2023-09-15: 424K2023-09-29: 464K2023-10-13: 495K2023-10-31: 600K2023-11-15: 762K2023-11-30: 958K2023-12-15: 947K2023-12-29: 874K2024-01-12: 880K2024-01-31: 937K
    the 31 Jan 2024 report24 earlier reportsnormal: 482K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 6 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 6 Feb 2024Filings record

    Director or officer change

  22. 25 Jan 2024Short interest and volume change

    had 880K shares sold short in the 12 Jan 2024 report, 2.1× the same report last year.

    Same report last year: 416K; its normal report is 469K.

    See the evidence
    This period
    880K (the 12 Jan 2024 report)
    Normal report (median of 24 earlier)
    469K
    Typical spread (median absolute deviation)
    61K
    How far from its usual level
    +4.6
    Same report last year
    416K
    History used
    2,205 days
    2023-01-13: 416K2023-01-31: 431K2023-02-15: 493K2023-02-28: 492K2023-03-15: 515K2023-03-31: 560K2023-04-14: 474K2023-04-28: 491K2023-05-15: 449K2023-05-31: 385K2023-06-15: 396K2023-06-30: 399K2023-07-14: 433K2023-07-31: 373K2023-08-15: 370K2023-08-31: 388K2023-09-15: 424K2023-09-29: 464K2023-10-13: 495K2023-10-31: 600K2023-11-15: 762K2023-11-30: 958K2023-12-15: 947K2023-12-29: 874K2024-01-12: 880K
    the 12 Jan 2024 report24 earlier reportsnormal: 469K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 11 Jan 2024Short interest and volume change

    had 874K shares sold short in the 29 Dec 2023 report, 2.0× the same report last year.

    Same report last year: 429K; its normal report is 457K.

    See the evidence
    This period
    874K (the 29 Dec 2023 report)
    Normal report (median of 24 earlier)
    457K
    Typical spread (median absolute deviation)
    49K
    How far from its usual level
    +5.8
    Same report last year
    429K
    History used
    2,191 days
    2022-12-30: 429K2023-01-13: 416K2023-01-31: 431K2023-02-15: 493K2023-02-28: 492K2023-03-15: 515K2023-03-31: 560K2023-04-14: 474K2023-04-28: 491K2023-05-15: 449K2023-05-31: 385K2023-06-15: 396K2023-06-30: 399K2023-07-14: 433K2023-07-31: 373K2023-08-15: 370K2023-08-31: 388K2023-09-15: 424K2023-09-29: 464K2023-10-13: 495K2023-10-31: 600K2023-11-15: 762K2023-11-30: 958K2023-12-15: 947K2023-12-29: 874K
    the 29 Dec 2023 report24 earlier reportsnormal: 457K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 28 Dec 2023Short interest and volume change

    had 947K shares sold short in the 15 Dec 2023 report, 2.1× the same report last year.

    Same report last year: 460K; its normal report is 455K.

    See the evidence
    This period
    947K (the 15 Dec 2023 report)
    Normal report (median of 24 earlier)
    455K
    Typical spread (median absolute deviation)
    39K
    How far from its usual level
    +8.5
    Same report last year
    460K
    History used
    2,177 days
    2022-12-15: 460K2022-12-30: 429K2023-01-13: 416K2023-01-31: 431K2023-02-15: 493K2023-02-28: 492K2023-03-15: 515K2023-03-31: 560K2023-04-14: 474K2023-04-28: 491K2023-05-15: 449K2023-05-31: 385K2023-06-15: 396K2023-06-30: 399K2023-07-14: 433K2023-07-31: 373K2023-08-15: 370K2023-08-31: 388K2023-09-15: 424K2023-09-29: 464K2023-10-13: 495K2023-10-31: 600K2023-11-15: 762K2023-11-30: 958K2023-12-15: 947K
    the 15 Dec 2023 report24 earlier reportsnormal: 455K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 12 Dec 2023Short interest and volume change

    had 958K shares sold short in the 30 Nov 2023 report, 2.5× the same report last year.

    Same report last year: 385K; its normal report is 441K.

    See the evidence
    This period
    958K (the 30 Nov 2023 report)
    Normal report (median of 24 earlier)
    441K
    Typical spread (median absolute deviation)
    50K
    How far from its usual level
    +6.9
    Same report last year
    385K
    History used
    2,162 days
    2022-11-30: 385K2022-12-15: 460K2022-12-30: 429K2023-01-13: 416K2023-01-31: 431K2023-02-15: 493K2023-02-28: 492K2023-03-15: 515K2023-03-31: 560K2023-04-14: 474K2023-04-28: 491K2023-05-15: 449K2023-05-31: 385K2023-06-15: 396K2023-06-30: 399K2023-07-14: 433K2023-07-31: 373K2023-08-15: 370K2023-08-31: 388K2023-09-15: 424K2023-09-29: 464K2023-10-13: 495K2023-10-31: 600K2023-11-15: 762K2023-11-30: 958K
    the 30 Nov 2023 report24 earlier reportsnormal: 441K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 28 Nov 2023Short interest and volume change

    had 762K shares sold short in the 15 Nov 2023 report, 1.4× the same report last year.

    Same report last year: 545K; its normal report is 441K.

    See the evidence
    This period
    762K (the 15 Nov 2023 report)
    Normal report (median of 24 earlier)
    441K
    Typical spread (median absolute deviation)
    50K
    How far from its usual level
    +4.3
    Same report last year
    545K
    History used
    2,147 days
    2022-11-15: 545K2022-11-30: 385K2022-12-15: 460K2022-12-30: 429K2023-01-13: 416K2023-01-31: 431K2023-02-15: 493K2023-02-28: 492K2023-03-15: 515K2023-03-31: 560K2023-04-14: 474K2023-04-28: 491K2023-05-15: 449K2023-05-31: 385K2023-06-15: 396K2023-06-30: 399K2023-07-14: 433K2023-07-31: 373K2023-08-15: 370K2023-08-31: 388K2023-09-15: 424K2023-09-29: 464K2023-10-13: 495K2023-10-31: 600K2023-11-15: 762K
    the 15 Nov 2023 report24 earlier reportsnormal: 441K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 5 Sep 2023Filings record

    Director or officer change

  28. 6 Jul 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 6 Jul 2023Filings record

    Director or officer change

  30. 6 Feb 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  31. 6 Feb 2023Filings record

    Director or officer change

  32. 15 Nov 2022Financials change

    spent $23.2M on capital projects in the quarter ended 30 Sep 2022, 3.1× the same quarter last year.

    Same quarter last year: $7.4M; its normal quarter is $7.5M.

    See the evidence
    This period
    $23.2M (the quarter ended 30 Sep 2022)
    Normal quarter (median of 8 earlier)
    $7.5M
    Typical spread (median absolute deviation)
    $186K
    How far from its usual level
    +15.7
    Same quarter last year
    $7.4M
    History used
    3,287 days
    2020-09-30: $7.4M2020-12-31: $7.3M2021-03-31: $7.5M2021-06-30: $7.1M2021-09-30: $7.4M2021-12-31: $7.7M2022-03-31: $10.0M2022-06-30: $11.9M2022-09-30: $23.2M
    the quarter ended 30 Sep 20228 earlier quartersnormal: $7.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  33. 3 Oct 2022Lobbying record

    A2 STRATEGIES, LLC OBO PHIBRO ANIMAL HEALTH CORPORATION: lobbying engagement terminated (VICKI J HICKS) (dated 31 Aug 2022)

  34. 30 Aug 2022Financials change

    spent $11.9M on capital projects in the quarter ended 30 Jun 2022, 1.7× the same quarter last year.

    Same quarter last year: $7.1M; its normal quarter is $7.5M.

    See the evidence
    This period
    $11.9M (the quarter ended 30 Jun 2022)
    Normal quarter (median of 8 earlier)
    $7.5M
    Typical spread (median absolute deviation)
    $186K
    How far from its usual level
    +4.4
    Same quarter last year
    $7.1M
    History used
    3,195 days
    2020-06-30: $10.1M2020-09-30: $7.4M2020-12-31: $7.3M2021-03-31: $7.5M2021-06-30: $7.1M2021-09-30: $7.4M2021-12-31: $7.7M2022-03-31: $10.0M2022-06-30: $11.9M
    the quarter ended 30 Jun 20228 earlier quartersnormal: $7.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  35. 25 Jul 2022Lobbying record

    PHIBRO ANIMAL HEALTH CORPORATION: lobbying engagement terminated (A2 STRATEGIES, LLC) (dated 31 Mar 2022)

  36. 2 Sep 2021Insiders record

    CORCORAN E THOMAS (director) bought 5,000 shares of PAHC ($118,400) (dated 1 Sep 2021)

  37. 15 Jul 2021Lobbying record

    A2 STRATEGIES, LLC OBO PHIBRO ANIMAL HEALTH CORPORATION: new lobbying registration (VICKI J HICKS) (dated 17 May 2021)

  38. 13 Jul 2021Lobbying record

    PHIBRO ANIMAL HEALTH CORPORATION: new lobbying registration (A2 STRATEGIES, LLC) (dated 31 Mar 2021)

  39. 17 Sep 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 17 Sep 2020Filings record

    Director or officer change

Showing the newest 40 of 64 entries; narrow the window or the kind of data to see older ones.

Not listed: 303 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001069899
Ticker
PAHC
Domain
pahc.com
Employer name
Phibro Animal Health Corporation (1 unverified)
Hq location
NJ|TEANECK|07666 (1 unverified)
Lobbying client
a2 strategies llc obo phibro animal health, phibro animal health, phibro animal health formerly philipp brothers chemical
Name
8861 Dice Road LLC, Abic Biological Laboratories Ltd, Abic Veterinary Products Ltd, California Water Technologies LLC(5) and 44 more
Uei
GJL5KLKJC3D1
Wikipedia
Phibro Animal Health
  • DOL H-1B labor condition applications and PERM certifications25 data points6 Apr 2020 to 17 Mar 2025
  • Federal lobbying disclosures (LDA)15 records, 200 data points30 Jun 1999 to 30 Sep 2026
  • SEC Form 13F institutional holdings450 data points30 Jun 2014 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)160 records12 Jan 2016 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)911 data points30 Jun 2011 to 30 Sep 2026
  • SEC Form 4 insider transactions165 records, 460 data points6 Jan 2016 to 2 Jun 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards6 data points10 Feb 2024 to 19 Dec 2024
  • Wikipedia pageviews11 data points11 Nov 2026 to 21 Nov 2026